Xianchen Liu

Aug 20, 2024 | cancernetwork.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy |Doris Makari |Rachel M. Layman | +2 more

BackgroundCardiovascular diseases (CVDs) can impact breast cancer treatment selection and clinical outcomes. A CDK4/6 inhibitor combined with endocrine therapy (ET) is now the standard of care as a first-line treatment for patients with hormone receptor–positive (HR+)/HER2-negative (HER2–) metastatic breast cancer. However, the effectiveness data of CDK4/6 inhibitors in patients with metastatic breast cancer and CVD are limited.

Mar 27, 2024 | futuremedicine.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThe authors thank all the people who contributed to the information used in this study.

Mar 22, 2024 | futuremedicine.com | Hope Rugo |Xianchen Liu |Benjamin Li |Lynn McRoy

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThe authors would like to thank all the people who contributed to the information used in this study. Competing interests disclosureHope S. Rugo reports sponsored research to her institution from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, Inc., F.

Dec 21, 2023 | mdpi.com | Yan Wu |Xianchen Liu |Martine C. Maculaitis |Benjamin Li

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Nov 2, 2023 | mdpi.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy

1. IntroductionIn 2018, more than 140,000 women were estimated to be living with metastatic breast cancer (mBC), a population expected to grow to more than 169,000 by 2025 [1]. Despite recent advances in treatment, the 5-year survival rate for patients with mBC remains low (31%), and it is estimated that more than 43,000 women in the United States (US) will die from breast cancer in 2023 [2].